Articles published by MaaT Pharma

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

January 20, 2026

From MaaT Pharma

Via Business Wire

MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

December 08, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Presents Updated Preclinical Data at SITC Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034

November 05, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update

November 04, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025

November 03, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

October 07, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Publishes Its Half Year 2025 Results and Provides a Business Update

September 17, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology

July 28, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe

July 02, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025

June 19, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease

June 13, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease

June 02, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress

May 14, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025

May 13, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

May 12, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034

April 28, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

April 08, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co

April 07, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

April 04, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

March 31, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results

March 27, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease

March 18, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013

March 11, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

January 21, 2025

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013 in acute Graft-versus-Host Disease

January 08, 2025

From MaaT Pharma

Via Business Wire

CORRECTING and REPLACING: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

December 09, 2024

From MaaT Pharma

Via Business Wire

MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

December 09, 2024

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

December 05, 2024

From MaaT Pharma

Via Business Wire

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

November 26, 2024

From MaaT Pharma

Via Business Wire

MaaT Pharma to Present Updates from Early Access Program at the 2024 ASH Annual Meeting Demonstrating Prolonged Long-Term Survival in Patients Receiving MaaT013 in aGvHD

November 07, 2024

From MaaT Pharma

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.